Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Fujifilm Toyama Chemical Co. Ltd. currently has a streamlined presence in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which is being handled by 1 distinct examiner. This indicates a specific and narrow focus for the company's current patent activities, as the entire active workload is concentrated within 1 distinct art unit.
SARA ELIZABETH TOWNSLEY is the busiest examiner for the company, with 1 busiest examiner pending office action. Given that the total number of pending office actions is also 1, this examiner is currently the sole arbiter for the company's pending matters. The prosecution strategy for Fujifilm Toyama Chemical Co. Ltd. is therefore entirely dependent on the interactions within this single art unit.
For legal teams, this data highlights a lack of complexity in the current portfolio's distribution. With only 1 distinct examiner to consider, practitioners can dedicate their resources to understanding the specific examination patterns of SARA ELIZABETH TOWNSLEY. The focus on 1 art unit within the Biotechnology & Pharmaceuticals sector suggests that the company is currently pursuing a specific technological path.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17907722 | THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION | TOWNSLEY, SARA ELIZABETH | 77d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17907722 | THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION | TOWNSLEY, SARA ELIZABETH | 77d |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17907722 | THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Non-Final OA | 77d | Pending | Sep 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial